Jasmit S Minhas1, Paige G Wickner2, Aidan A Long3, Aleena Banerji3, Kimberly G Blumenthal4. 1. Department of Medicine, Lahey Clinic, Burlington, Massachusetts. Electronic address: jasmit.minhas@lahey.org. 2. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 3. Harvard Medical School, Boston, Massachusetts; Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 4. Harvard Medical School, Boston, Massachusetts; Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts; Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Vancomycin is a broad-spectrum antibiotic whose use may be limited by adverse drug reactions (ADRs). Although vancomycin toxic effects are known, there are limited data on vancomycin hypersensitivity reactions (HSRs). OBJECTIVE: To understand the most commonly reported vancomycin HSRs through systematic case review. METHODS: We performed a literature search for English-language case reports and series from 1982 through 2015 (last search July 31, 2015) on Ovid MEDLINE and PubMed. The search included the subject heading vancomycin with the subheading adverse effects and separate text searches for vancomycin with a list of specified HSRs. References of identified articles were reviewed to find additional articles. Clinical data were collected and summarized. RESULTS: Of 201 identified articles, 84 were screened and 57 fully assessed; these 57 articles contained 71 vancomycin HSR cases that were included in analysis. Vancomycin HSRs were immediate (anaphylaxis, n = 7) and nonimmediate (n = 64). Nonimmediate HSRs included linear IgA bullous dermatosis (LABD, n = 34), drug rash eosinophilia and systemic symptoms (DRESS) syndrome (n = 16), acute interstitial nephritis (AIN, n = 8), and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN, n = 6). Median times of vancomycin therapy before HSR onset was 7 days (interquartile range [IQR], 4-10 days) for LABD, 9 days (IQR, 9-22 days) for SJS/TEN, 21 days (IQR, 17-28 days) for DRESS syndrome, and 26 days (IQR, 7-29 days) for AIN. Overall, 11 patients (16%) died, and 4 (6%) had deaths attributed to the HSR. CONCLUSION: Vancomycin causes a variety of HSRs; the most commonly identified were nonimmediate HSRs, with LABD being most frequent. We observed a high frequency of HSR mortality. Further data are needed to understand the frequency and severity of vancomycin HSRs.
BACKGROUND:Vancomycin is a broad-spectrum antibiotic whose use may be limited by adverse drug reactions (ADRs). Although vancomycin toxic effects are known, there are limited data on vancomycinhypersensitivity reactions (HSRs). OBJECTIVE: To understand the most commonly reported vancomycin HSRs through systematic case review. METHODS: We performed a literature search for English-language case reports and series from 1982 through 2015 (last search July 31, 2015) on Ovid MEDLINE and PubMed. The search included the subject heading vancomycin with the subheading adverse effects and separate text searches for vancomycin with a list of specified HSRs. References of identified articles were reviewed to find additional articles. Clinical data were collected and summarized. RESULTS: Of 201 identified articles, 84 were screened and 57 fully assessed; these 57 articles contained 71 vancomycinHSR cases that were included in analysis. Vancomycin HSRs were immediate (anaphylaxis, n = 7) and nonimmediate (n = 64). Nonimmediate HSRs included linear IgA bullous dermatosis (LABD, n = 34), drug rash eosinophilia and systemic symptoms (DRESS) syndrome (n = 16), acute interstitial nephritis (AIN, n = 8), and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN, n = 6). Median times of vancomycin therapy before HSR onset was 7 days (interquartile range [IQR], 4-10 days) for LABD, 9 days (IQR, 9-22 days) for SJS/TEN, 21 days (IQR, 17-28 days) for DRESS syndrome, and 26 days (IQR, 7-29 days) for AIN. Overall, 11 patients (16%) died, and 4 (6%) had deaths attributed to the HSR. CONCLUSION:Vancomycin causes a variety of HSRs; the most commonly identified were nonimmediate HSRs, with LABD being most frequent. We observed a high frequency of HSR mortality. Further data are needed to understand the frequency and severity of vancomycin HSRs.
Authors: Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine Journal: Am J Health Syst Pharm Date: 2009-01-01 Impact factor: 2.637
Authors: F R Bruniera; F M Ferreira; L R M Saviolli; M R Bacci; D Feder; M da Luz Gonçalves Pedreira; M A Sorgini Peterlini; L A Azzalis; V B Campos Junqueira; F L A Fonseca Journal: Eur Rev Med Pharmacol Sci Date: 2015-02 Impact factor: 3.507
Authors: Katherine C Konvinse; Jason A Trubiano; Rebecca Pavlos; Ian James; Christian M Shaffer; Cosmin A Bejan; Ryan J Schutte; David A Ostrov; Mark A Pilkinton; Misha Rosenbach; Jeffrey P Zwerner; Kristina B Williams; Jack Bourke; Patricia Martinez; Francois Rwandamuriye; Abha Chopra; Mark Watson; Alec J Redwood; Katie D White; Simon A Mallal; Elizabeth J Phillips Journal: J Allergy Clin Immunol Date: 2019-02-16 Impact factor: 10.793
Authors: Santiago Alvarez-Arango; Eric Oliver; Olive Tang; Trisha Saha; Corinne A Keet; N Franklin Adkinson; Donald W MacGlashan Journal: Clin Exp Allergy Date: 2021-02-21 Impact factor: 5.401
Authors: Santiago Alvarez-Arango; Sharmitha Yerneni; Olive Tang; Li Zhou; Christian M Mancini; Suzanne V Blackley; Corinne Allison Keet; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2020-10-01